|
The TAILORx trial: individualized options for treatment
Albert Einstein College of Medicine, Montefiore-Einstein Cancer Center, Bronx, NY
Because predicting treatment benefit is imprecise, when faced with making a decision on whether to accept adjuvant chemotherapy, many patients with ER-positive breast cancer and their clinicians err on the side of overtreatment. The TAILORx trial will attempt to reduce overtreatment by integrating a molecular diagnostic test into clinical decision making; identifying the utility of chemotherapy in patients where the molecular test gives a result of uncertain clinical significance; and serving as a resource to evaluate new molecular tests as they develop. This article describes the trial and how clinicians can enroll their patients.
| Commun Oncol 2006;3:494–496 | full text |  135 kb |